<DOC>
	<DOCNO>NCT00749021</DOCNO>
	<brief_summary>This multicenter , randomize , open-label study . 40 patient follow period 12 month . All consent enrolled patient receive either 0.5mg 2.0mg intravitreal ranibizumab injection .</brief_summary>
	<brief_title>Ranibizumab Treating Submacular Vascularized Pigment Epithelial Detachments</brief_title>
	<detailed_description />
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Dissociative Disorders</mesh_term>
	<mesh_term>Retinal Detachment</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patient 50 year old Patient willing participate study follow criterion protocol study . Patient involve another clinical trial . Ability understand inform consent willingness sign consent . Presence submacular vascularize fibrovascular PED . Central foveal involvement PED CNV due age relate macular degeneration . PED less equal 12 disc area size BCVA ETDRS great equal 19 letter less equal 69 letter ( 20/400 20/40 ) Central 1mm foveal thickness great equal 250 micron OCT . Greatest linear diameter submacular hemorrhage need less 50 % entire PED . Submacular fibrosis need less 50 % entire PED . Sufficiently clear medium ( cornea , anterior chamber , lens , vitreous ) OCT , FA , FP . Intraocular pressure 25 mm less study eye , without use ocular hypotensive agent . Pregnancy lactation Premenopausal woman use adequate contraception Known serious allergy ranibizumab , fluorescein dye , drug pupillary dilation , topical anesthetic , sterilize solution Contraindication pupillary dilation study eye Any condition ( include inability read visual acuity chart language barrier ) may preclude patient 's ability comply study protocol requirement Presence advance systemic condition endstage disease , advance Alzheimer syndrome , endstage cancer , etc. , likely prevent patient complete study . Previous therapeutic radiation region study eye . Prior antivascular endothelial factor therapy within 30 day . More 3 session prior antiVEGF therapy . More 1 prior photodynamic therapy ( PDT ) Prior triamcinolone past 6 month dexamethasone past 1 month . Prior retinal pigment epithelial ( RPE ) tear study eye . Prior ocular surgery ( except YAG laser capsulotomy ) study eye within past 90 day . Anticipated ocular surgery ( except YAG laser capsulotomy ) next 12 month . Prior therapy AMD ( except mineral vitamin ) , include laser , within past 30 day . Prior intraocular periocular corticosteroid therapy within past 120 day Prior vitrectomy Presence cause CNV PED due AMD . Presence substantial ocular disease ( CNV PED ) may compromise vision study eye and/or confound interpretation date ; e.g . substantial cataract , concomitant diabetic retinopathy affect macula , advance glaucoma , optic neuritis , optic neuropathy atrophy , mark macular atrophy , ocular vascular occlusion , history retinal detachment , uveitis , viral form chorioretinitis , etc . Presence ocular disease AMD affect study eye , i.e . presume ocular histoplasmosis syndrome , angioid streak , pathologic myopia ( spherical equivalent great equal 8 diopter myopia axial length great equal 25 mm ) , choroidal rupture , multifocal choroiditis , etc . Active ocular infection ( i.e. , bacterial , viral , parasitic , fungal ) either eye screening Day 0 .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>choroidal neovascularization</keyword>
	<keyword>vascularize</keyword>
</DOC>